Immatics

Immatics Liabilities

The The Liabilities of Immatics (IMTX) as of Nov 22, 2026 is 78.24 M EUR. In the previous year, The Liabilities was 121.30 M EUR — a change of -35.50% (lower).

Liabilities

78.24 MEUR

YoY

-35.50%

Last updated:

In 2025, Immatics's total liabilities amounted to 78.24 M EUR, a -35.50% difference from the 121.30 M EUR total liabilities in the previous year.

The Immatics Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
175.11 M EUR
Jan 1, 2020
150.39 M EUR
Jan 1, 2021
150.58 M EUR
Jan 1, 2022
194.66 M EUR
Jan 1, 2023
284.88 M EUR
Jan 1, 2024
121.30 M EUR
Jan 1, 2025
78.24 M EUR
The Immatics Liabilities history
YEARLiabilitiesYoY
78.24 MEUR-35.50%
121.30 MEUR-57.42%
284.88 MEUR+46.35%
194.66 MEUR+29.27%
150.58 MEUR+0.13%
150.39 MEUR-14.12%
175.11 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immatics Stock analysis

What does Immatics do? Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors through Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). The company's pipeline includes eight therapeutic programs, with four in clinical trials: IMA201 (MAGEA4/8), IMA202 (MAGEA1), ACTolog IMA 101 (Multi-target pilot trial), and IMA203 (PRAME). Four programs are in preclinical development, such as IMA204 (COL6A3) and IMA401 (Cancer testis antigen). Immatics generates revenue through licensing agreements and potential future sales of its therapies, targeting pharmaceutical companies and research institutions seeking advanced cancer treatments. The company's clinical-stage therapies are designed to enable robust T-cell responses against cancer targets, with programs like IMA201 and IMA202 focused on solid tumors. IMA203 addresses both hematological and solid cancers, while preclinical programs like IMA401 and IMA402 target cancer testis antigens. Immatics partners with biopharmaceutical firms to advance its pipeline, leveraging its TCR technology platform to develop therapies for unmet medical needs in oncology. Immatics' revenue model relies on strategic partnerships and licensing deals with pharmaceutical companies, which fund clinical development and gain access to its proprietary TCR platform. The firm's focus on solid tumors and hematological cancers attracts interest from major biopharmaceutical players looking to expand their oncology portfolios. Through its eight therapeutic programs, Immatics aims to deliver innovative treatments that address high unmet medical needs in cancer therapy. Immatics is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Immatics's Liabilities

Immatics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Immatics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Immatics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Immatics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Immatics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Immatics stock

The Liabilities of Immatics is 78.24 M EUR in 2025.

The Liabilities of Immatics changed from 121.30 M EUR to 78.24 M EUR, representing a -35.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Immatics since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Immatics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Immatics

All Key Metrics — Immatics